Peter Ruehlman

A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers

Johanna C. Bendell, Ahmed Zakari, Evan Lang et al. · Cancer Investigation · 2016 · 17 citations

Medicine, Oncology, Pharmacology +15

Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing

James Suh, Alexa B. Schrock, Adrienne Johnson et al. · The Oncologist · 2018 · 13 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET).

Irfan Firdaus, Kent C. Shih, Ahmed Zakari et al. · Journal of Clinical Oncology · 2012 · 12 citations

Medicine, Pharmacology, Pharmacotherapy +15